Sirtex wins $1.3m Start grant
Thursday, 28 October, 2004
Sirtex (ASX: SRX) has been awarded a AUD$1.311 million R&D Start grant from AusIndustry to commercialise its Targeted Hyperthermia Therapy.
Targeted Hyperthermia Therapy uses the company's microsphere platform technology to deliver magnetic nanoparticles to tumours, followed by treatment with an alternating magnetic field to heat up the tumour causing death of the cancer cells.
The company has recently overcome some technical issues regarding the scale up of the treatment from animals to humans.
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
Widespread resistance to common antibiotics is increasing: WHO
Increasing resistance to essential antibiotics poses a growing threat to global health, with one...
